Dr. Fernando Martinez, a clinical specialist in lung diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), is the newest member of the scientific and medical advisory board of ProterixBio, the company announced. His appointment as scientific and medical advisor reflects the company’s focus on solutions to improve care…
ProterixBio Names Dr. Fernando Martinez of Weill Cornell to Its Scientific Advisory Board
University of California, San Francisco, researchers reported that markers of cellular senescence — a process preventing cells from multiplying uncontrollably — are overly abundant in cells lining lung alveoli in patients with idiopathic pulmonary fibrosis (IPF). The study, “miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial…
Lowering the numbers of interleukin-10 (IL-10)-producing immune B-cells in a mouse model protected the animals from developing fibrosis after exposure to silica, according to a recent report by researchers in China. The study, “Role of IL-10-producing regulatory B cells in modulating T-helper cell immune responses during silica-induced lung…
Researchers from The Netherlands found that mice producing high levels of protein C which prevents blood coagulation, develop less severe pulmonary fibrosis; and the milder disease course is linked to lower numbers of immune cells in the lung. The study, “High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis,“ published in…
Two clinical hallmarks of patients with idiopathic pulmonary fibrosis (IPF), traction bronchiectasis and honeycombing, may be aspects of one continuous process of lung remodeling rather than distinct entities, as previously thought, according to researchers in Italy. Traction bronchiectasis refers to an irreversible dilation of bronchi, and honeycombing to the diffuse pulmonary…
A recent study published in the journal PLOS One, found two members of a class of proteins called surfactant proteins (SPs) at increased levels as a result of lung fibrosis and suggests that future studies could reveal the proteins, SP-A and SP-D, as markers of disease severity. Pulmonary emphysema and idiopathic pulmonary fibrosis (IPF) are defined…
The U.S. Patent and Trademark Office issued a new patent to iBio, covering the company’s rights for the use of endostatin-related peptides with therapeutic potential in a number of fibrotic diseases, including scleroderma and idiopathic pulmonary fibrosis (IPF). The patent, US 9,365,616, is titled “Use of Endostatin Peptides for the Treatment…
Pulmatrix, a clinical stage biopharmaceutical company, recently released an animated life sciences video describing their new dry powder inhaler system called Isperse for lung disease patients.
OFEV (nintedanib) is effective for a wide range of idiopathic pulmonary fibrosis (IPF) patients according to Boehringer Ingelheim, the company that developed the drug.
After reading a story in a newspaper, Cloyd Goley of Farmersville, Ohio, who has pulmonary fibrosis, felt newly hopeful. The article, published in the Dayton Daily News, told the story of the Rev. Joseph Kyles, a Chicago minister with  pulmonary fibrosis who was able to return to his work after undergoing a double-lung transplant. “It’s…
